Management of ovarian stromal cell tumors

被引:265
作者
Colombo, Nicoletta
Parma, Gabriella
Zanagnolo, Vanna
Insinga, Alessandra
机构
[1] European Inst Oncol, Div Gynecol Oncol, I-20141 Milan, Italy
[2] European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy
[3] Univ Milano Bicocca, Milan, Italy
关键词
BLEOMYCIN COMBINATION CHEMOTHERAPY; GRANULOSA-CELL; PROGNOSTIC FACTORS; CLINICOPATHOLOGICAL ANALYSIS; MAMMARY-GLAND; SERUM INHIBIN; CIS-PLATINUM; STEM-CELLS; RECURRENT; CISPLATIN;
D O I
10.1200/JCO.2007.11.1005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To describe the clinical management of ovarian stromal cell tumors, which are a heterogeneous group of neoplasms that develop from the sex cords and the ovarian stroma. Design We reviewed the current evidence on the clinical management of these relatively rare ovarian malignancies, which are typically detected at an early stage and may recur as late as 30 years following the initial treatment. The overall prognosis is favorable with a long-term survival ranging from 75% to 90% for all stages. Adult granulosa cell tumor (GCT) is the most common malignancy among these tumors. Results Surgery is the cornerstone of initial treatment. In women of childbearing age and with disease limited to one ovary, a fertility-sparing surgery can be a reasonable approach. Tumor stage represents the most important clinical parameter of prognostic relevance. The value of postoperative adjuvant therapy for high-risk patients has not been proven by prospective randomized studies. Platinum-based chemotherapy is used currently for patients with advanced stages or recurrent disease, with an overall response rate of 63% to 80%. Taxane and platinum combination chemotherapy seems to be a reasonable candidate for future trials. Little evidence exists for the use of radiation or hormonal therapy, and these modalities should be restricted to selected cases. Given the propensity of GCT for late relapse, prolonged follow-up is required. Conclusion Surgery remains the most effective treatment for ovarian stromal tumors and, whenever feasible, for relapsing disease. Platinum-based chemotherapy is currently used in metastatic or recurrent tumors.
引用
收藏
页码:2944 / 2951
页数:8
相关论文
共 68 条
[1]   PROGNOSTIC FACTORS IN GRANULOSA-CELL TUMORS [J].
BJORKHOLM, E ;
SILFVERSWARD, C .
GYNECOLOGIC ONCOLOGY, 1981, 11 (03) :261-274
[2]   Serum inhibin and disease status in women with ovarian granulosa cell tumors [J].
Boggess, JF ;
Soules, MR ;
Goff, BA ;
Greer, BE ;
Cain, JM ;
Tamimi, HK .
GYNECOLOGIC ONCOLOGY, 1997, 64 (01) :64-69
[3]   Megestrol activity in recurrent adult type granulosa cell tumour of the ovary [J].
Briasoulis, E ;
Karavasilis, V ;
Pavlidis, N .
ANNALS OF ONCOLOGY, 1997, 8 (08) :811-812
[4]   Management of non-epithelial ovarian tumours [J].
Bridgewater, JA ;
Rustin, GJS .
ONCOLOGY, 1999, 57 (02) :89-98
[5]   The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors [J].
Brown, J ;
Shvartsman, HS ;
Deavers, MT ;
Ramondetta, LM ;
Burke, TW ;
Munsell, MF ;
Gershenson, DM .
GYNECOLOGIC ONCOLOGY, 2005, 97 (02) :489-496
[6]   Can ovarian infertility be treated with bone marrow- or ovary-derived germ cells? [J].
Bukovsky, A .
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2005, 3 (1)
[7]   CISPLATIN, VINBLASTINE, AND BLEOMYCIN COMBINATION CHEMOTHERAPY IN METASTATIC GRANULOSA-CELL TUMOR OF THE OVARY [J].
COLOMBO, N ;
SESSA, C ;
LANDONI, F ;
SARTORI, E ;
PECORELLI, S ;
MANGIONI, C .
OBSTETRICS AND GYNECOLOGY, 1986, 67 (02) :265-268
[8]   Review of the granulosa-theca cell tumors from the Emil Novak Ovarian Tumor Registry [J].
Cronjé, HS ;
Niemand, I ;
Bam, RH ;
Woodruff, JD .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 180 (02) :323-327
[9]   DEMONSTRATION OF AN FSH RECEPTOR IN A FUNCTIONING GRANULOSA-CELL TUMOR - EFFECT OF GONADOTROPIN TREATMENT ON ITS VIABILITY FOLLOWING TRANSPLANTATION TO NUDE MICE [J].
DAVY, M ;
TORJESEN, PA ;
AAKVAAG, A .
ACTA ENDOCRINOLOGICA, 1977, 85 (03) :615-623
[10]   In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells [J].
Dontu, G ;
Abdallah, WM ;
Foley, JM ;
Jackson, KW ;
Clarke, MF ;
Kawamura, MJ ;
Wicha, MS .
GENES & DEVELOPMENT, 2003, 17 (10) :1253-1270